The SeroSelectTB test will be evaluated at the Wallacedene, Scottsdene and Bloekombos health clinics in the Northern Health District of Cape Town, South Africa. TB suspects self-reporting to the study sites will be randomised in two arms: standard-of-care or SeroSelectTB. In South Africa, 2314 TB suspects will be enrolled in each study arm.

 

This section will be updated as the clinical trial proceeds.